Abstract
It has become apparent in the last years that metal ion homeostasis and its dysfunction which results in increased accumulation in brain, notably of copper, iron and zinc, may be associated with a number of neurodegenerative diseases, such that chelation therapy may be one therapeutic option. We briefly outline chelators currently available together with strategies to develop new chelators capable of crossing the blood-brain-barrier. The homeostasis of iron in brain together with changes in brain iron with ageing are reviewed as well as the role of iron in Parkinson’s disease, and the potential of chelation therapy in PD. Copper and zinc homeostasis in brain and ageassociated changes are then outlined, along with a discussion of the possible involvement of Zn, Cu and Fe in Alzheimer’s disease. We conclude with a brief summary of chelation therapy in AD.
Keywords: chelation, neurodegeneration, iron, copper, zinc
Current Medicinal Chemistry
Title:Chelating Agents for Neurodegenerative Diseases
Volume: 19 Issue: 17
Author(s): R. J. Ward, D. T. Dexter and R. R. Crichton
Affiliation:
Keywords: chelation, neurodegeneration, iron, copper, zinc
Abstract: It has become apparent in the last years that metal ion homeostasis and its dysfunction which results in increased accumulation in brain, notably of copper, iron and zinc, may be associated with a number of neurodegenerative diseases, such that chelation therapy may be one therapeutic option. We briefly outline chelators currently available together with strategies to develop new chelators capable of crossing the blood-brain-barrier. The homeostasis of iron in brain together with changes in brain iron with ageing are reviewed as well as the role of iron in Parkinson’s disease, and the potential of chelation therapy in PD. Copper and zinc homeostasis in brain and ageassociated changes are then outlined, along with a discussion of the possible involvement of Zn, Cu and Fe in Alzheimer’s disease. We conclude with a brief summary of chelation therapy in AD.
Export Options
About this article
Cite this article as:
J. Ward R., T. Dexter D. and R. Crichton R., Chelating Agents for Neurodegenerative Diseases, Current Medicinal Chemistry 2012; 19 (17) . https://dx.doi.org/10.2174/092986712800609689
DOI https://dx.doi.org/10.2174/092986712800609689 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluparoxan: A Comprehensive Review of its Discovery, Adrenergic and CNS Activity and Treatment of Cognitive Dysfunction in Central Neurodegenerative Diseases
Mini-Reviews in Medicinal Chemistry Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches
Current Vascular Pharmacology Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design Circular RNAs in Eukaryotic Cells
Current Genomics Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology The Effects of Gender and CYP46 and Apo E Polymorphism on 24S-Hydroxycholesterol Levels in Alzheimers Patients Treated with Statins
Current Alzheimer Research Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals Smart Community Care System: Ambient Intelligence Using Radio Frequency Identification (RFID) and Mobile Agent
Recent Patents on Computer Science Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Role of Acetylcholinesterase Inhibitors in the Metabolism of Amyloid Precursor Protein
Current Drug Targets - CNS & Neurological Disorders Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Neuronal-glial Interactions Define the Role of Nitric Oxide in Neural Functional Processes
Current Neuropharmacology Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Ramelteon in the Treatment of Delirium: New Perspectives from Reported Findings and a Case Observation
Current Drug Therapy Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients
Reviews on Recent Clinical Trials Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology